Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.
Lumasiran 在一型原發性高草酸尿患者中的療效與安全性:來自第三期臨床試驗的結果。
Kidney Int Rep 2024-07-31
Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
原發性高草酸血症患兒接受RNAi治療後,是否可以停止夜間過度水化療法?
J Nephrol 2023-07-18
Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
多中心長期真實世界數據:Lumasiran治療原發性高草酸血症1型患者。
Kidney Int Rep 2024-02-06
Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.
羥丙酮酸尿症小兒患者的 Lumasiran 治療:意大利一項富同情心使用計劃中的實際數據。
Clin Kidney J 2024-05-14
Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.
中國人群原發性高草酸尿症的突變特徵及目前國際診斷與治療現狀。
Kidney Dis (Basel) 2024-08-12